Zenas BioPharma ZBIO
NASDAQ ZBIO
$28.68 +0.11 (+0.40%)
As of: Nov 10, 2026 · 2:49 PM EST

Zenas BioPharma (ZBIO) EBT Margin (2023 - 2026)

Updated

Zenas BioPharma (ZBIO) reported EBT Margin of -11134.20% for Q2 2026.

Analysis

Zenas BioPharma (ZBIO) EBT Margin (2023 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Zenas BioPharma's EBT Margin came in at -48416.40%, down 47237.99 percentage points year-over-year; for FY2025, it was -3778.16%, down 646.98 percentage points from FY2024.

  • By year, EBT Margin came in at -3131.18% in FY2024 (-3057.53 pp) and -73.65% in FY2023.
  • The Q2 2026 figure ranks as the highest quarterly EBT Margin since Q1 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 0.13%
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 27.75%
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 30.74%
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 29.63%
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn 18.19%
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 45.21%
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 36.90%
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 20.41%
10 Zenas BioPharma 1.84 Bn 1.17 Bn - -11,134.20%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -11,134.20%
Mar 31, 2025 -337.78%
Dec 31, 2024 -1,043.50%
Sep 30, 2023 71.25%
API Access

Zenas BioPharma EBT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebt-margin&ticker=ZBIO&period=max&api_key=YOUR_API_KEY